At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Bariatric Surgery (procedure)
- How long the study runs
- Study runs about 88 months (dates as stated)
- About the drug or intervention
- Bariatric Surgery — procedure: Already clinically indicated surgical procedures
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 153
- Started
- 2019-03-05
- Last checked
- 2026-06
Plain English Summary
What is this study?
- • Testing a new treatment for non-alcoholic fatty liver disease
- • Clinical study - 153 participants
- • To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with non-alcoholic fatty liver disease
Where?
- • London - Homerton University Hospital Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
More detail
In this study, the investigators will collect tissue, blood, stool, urine and saliva samples at the same time in order to enable a comprehensive disease phenotyping and ability to compare immunological, microbiological and metabolic features in patients with varying stages of NAFLD and healthy controls. To date there are limited published data evaluating simultaneously-obtained samples from adipose, gut and liver tissue and peripheral blood in NAFLD. The majority of participants in this study will be recruited from the bariatric surgery services enabling multiple tissue samples to be collected at time of surgery with minimal additional risk to participants.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Age ≥18 years
- ✓Confirmed non-alcoholic Fatty liver disease (diagnosed clinically, radiologically or histologically)
- ✓If diabetic, Diagnosed with Type 2 Diabetes Mellitus
- ✓Healthy Control: no diagnosis of any liver condition including NAFLD
- ✓o NAFLD excluded by Fibroscan Controlled Attenuation Parameter (CAP) score of \<222 dB/m
Who cannot take part
- ✗Unwilling or unable to give agreement to take part
- ✗Type 1 Diabetes Mellitus
- ✗Other form of liver disease (other than NAFLD)
- ✗o Viral hepatitis, Auto-immune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis,...
- ✗Taking medication associated with liver dysfunction (except methotrexate)
See the full criteria
Where Is This Study? (1 UK site)
Homerton University Hospital Foundation Trust
London E9 6SR, United Kingdom
How to Get in Touch
William Alazawi, MD Phd
Sponsor contactCONTACT
James Brindley, Md Phd
Sponsor contactCONTACT